A-620223
A-620223 is a PARP-1 inhibitor with a Ki of 8 nM against PARP-1 and EC50 of 3 nM in a whole cell assay. A-620223 demonstrates good in vivo efficacy in a B16F10 subcutaneous murine melanoma model in combination with Temozolomide (TMZ) (HY-17364) and in an MX-1 breast xenograph model in combination with Cisplatin (HY-17394) . A-620223 can be used for the studies of melanoma and breast cancer[1].
Product Specifications
CAS Number
[272769-49-0]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
PARP
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Field of Research
Cancer
Purity
98.84
Smiles
CCCN(CC1)CCC1C2=NC3=C(C(N)=O)C=CC=C3N2
Molecular Formula
C16H22N4O
Molecular Weight
286.37
Precautions
H302, H315, H319, H335
References & Citations
[1]Penning TD, et al. Discovery and SAR of 2- (1-propylpiperidin-4-yl) -1H-benzimidazole-4-carboxamide: A potent inhibitor of poly (ADP-ribose) polymerase (PARP) for the treatment of cancer. Bioorg Med Chem. 2008 Jul 15;16 (14) :6965-75.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound2
Clinical Information
No Development Reported
Isoform
PARP1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
250427-AP 100 µL
PRAGMIN (Homolog of rat pragma of Rnd2, DKFZp761P0423) (AP) discontinued
Ask
View Details